Indication
Central Nervous System Progression
1 clinical trial
2 products
Clinical trial
A Phase 1 Study of Temozolomide in Combination With Targeted Therapy for NSCLC Patients With CNS Progression on Either Osimertinib or LorlatinibStatus: Completed, Estimated PCD: 2022-04-25
Product
Temozolomide + OsimertinibProduct
Temozolomide + Lorlatinib